Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-123.Shawver,L.K. et al. (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 1, 117-123.Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy....
In fibrotic lung diseases, tyrosine kinases promote abnormal growth of scar tissue which replaces normal lung tissue, progressively affecting lung function. Pulmonary tyrosine kinase inhibitors prevent tyrosine kinases from promoting scar tissue growth in the lungs. Pulmonary tyrosine kinase inhibitors preven...
FULL PAPER British Journal of Cancer (2017) 116, 1366–1373 | doi: 10.1038/bjc.2017.88 Keywords: heart failure; tyrosine kinase-targeting drugs; cardio-oncology; adverse effects Tyrosine kinase-targeting drugs-associated heart failure N Gronich*,1, I Lavi1, O Barnett-Griness1, W Saliba1, D...
Thus, inhibitors that block the activity of tyrosine kinases and their subsequent signaling pathways play a key role in the development of therapeutic strategies for cancer and the other enzyme-related pathologies. Generally, there are two classes of protein tyrosine kinase inhibitors. One type binds...
Proposed cellular mechanisms ofon- and off-targeteffects of multi-kinase inhibitors. Off-target toxic effects are a result of the inhibition of kinases other than the intended target of the TKIs. Off-target blockage of AMPK by drugs like sunitinib leads to superoxide production in mitochondria res...
Finally, we discuss the effects of BTK inhibitors on tumor growth in solid malignancies in the context of the function of myeloid cells in the tumor environment. BTK structure BTK is one of the five members of the TEC family of non-receptor tyrosine kinases - along with tyrosine kinase ...
Knowing that there are presently no approved drugs or other therapeutics for the treatment of multidrug-resistant cancers, in recent years, studies have investigated the repurposing of tyrosine kinase inhibitors (TKIs) to act as agents against MDR mediated by ABCB1 and/or ABCG2. SKLB610 is a ...
- 《Investigational New Drugs》 被引量: 30发表: 2012年 A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metast... Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC,...
Bruton's tyrosine kinase (BTK) is a non-receptor protein kinase that plays a crucial role in various biological processes, including immune system function and cancer development. Therefore, inhibition of BTK has been proposed as a therapeutic strategy f
This invention comprises (among other things) chemically modified protein ty rosine kinase inhibitors (PTK inhibitors) that possess certain advantages over PTK inhibitors lacking the chemical modification. The chemically modified PTK inhibitors described herein relate to and/or have application(s) in (amo...